title: A randomized, double-masked, placebo-controlled clinical trial of multivitamin supplementation for age-related lens opacities. Clinical trial of nutritional supplements and age-related cataract report no. 3.
abstract: OBJECTIVE
  To evaluate the effect of a multivitamin/mineral supplement on development or progression of age-related lens opacities.
  
  
  METHODS
  Randomized, double-masked, single center, placebo-controlled clinical trial.
  
  
  METHODS
  One thousand twenty participants, 55 to 75 years old and with early or no cataract, were randomly assigned to a daily tablet of a multivitamin/mineral formulation or a placebo.
  
  
  METHODS
  Baseline and annual lens photographs were graded for severity of lens opacities according to a modification of the Age-Related Eye Disease Study system for classifying cataracts.
  
  
  METHODS
  The primary outcome was a prespecified increase from baseline in nuclear, cortical, or posterior subcapsular cataract (PSC) opacity grades or cataract surgery. Secondary outcomes included an increase in type-specific opacity grades, cataract surgery, and visual acuity (VA) loss from baseline > or =15 letters.
  
  
  RESULTS
  Participants were observed for an average of 9.0+/-2.4 years. There was a decrease in total lens events in participants assigned to the multivitamin/mineral formulation compared with those assigned to the placebo (hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.68-0.98; P = 0.03). Nuclear events were significantly less common (HR, 0.66; 95% CI, 0.50-0.88; P = 0.004) and PSC events significantly more common (HR, 2.00; 95% CI, 1.35-2.98; P<0.001) in participants taking the multivitamin/mineral formulation than in those assigned to the placebo. No statistically significant treatment effects were seen for cortical opacities, moderate VA loss, or cataract surgery.
  
  
  CONCLUSIONS
  Lens events were less common in participants who took the multivitamin/mineral formulation, but treatment had opposite effects on the development or progression of nuclear and PSC opacities, the 2 most visually important opacity subtypes.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Maraini
authors.forename: Sally L
authors.initials: SL
authors.lastname: Williams
authors.forename: Robert D
authors.initials: RD
authors.lastname: Sperduto
authors.forename: Frederick
authors.initials: F
authors.lastname: Ferris
authors.forename: Roy C
authors.initials: RC
authors.lastname: Milton
authors.forename: Traci E
authors.initials: TE
authors.lastname: Clemons
authors.forename: Francesco
authors.initials: F
authors.lastname: Rosmini
authors.forename: Luigina
authors.initials: L
authors.lastname: Ferrigno
mesh_terms: D000368:Aged; D002386:Cataract / Q000145:classification / Q000188:drug therapy* / Q000503:physiopathology*; D002387:Cataract Extraction / Q000706:statistics & numerical data; D019587:Dietary Supplements / Q000009:adverse effects; D018450:Disease Progression; D004311:Double-Blind Method; D004415:Dyspepsia / Q000139:chemically induced; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D014792:Visual Acuity; D014815:Vitamins / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D014815:Vitamins